Bladder cancer is a urologic malignancy arising primarily from epithelial cells lining the bladder. In the vast majority of cases (>90%), bladder cancer manifests as transitional (urothelial) cell carcinoma (TCC). The remaining cases manifest as squamous cell carcinoma, adenocarcinoma, and in rare instances, carcinosarcoma. Bladder cancer is classified under the International Classification of Diseases, Tenth Revision (ICD-10) code C67. It is the ninth most common cancer in men and women worldwide, with the highest recurrence rate of any malignancy.

It is estimated that the bladder cancer market in the 7MM was valued at $360M in 2015. This market includes sales of approved, branded therapies and those of off-label drugs. Of the countries/regions in the 7MM, the 5EU contributed 45% of sales, while the US and Japan contributed 39% and 16%, respectively. By 2025, it is expected that the bladder cancer market in the 7MM to reach $1.17B, tripling in size, at a Compound Annual Growth Rate (CAGR) of 12.5%.

In 2025, the US will contribute 49% of sales, while the 5EU and Japan will contribute 35% and 16%, respectively. During the forecast period, the US market is expected to grow the fastest, at a CAGR of 15.2%, owing to the earlier and more widespread usage of programmed cell death protein 1 (PD-1) modulators. The 5EU market will grow the slowest, at a CAGR of 9.5%, and the Japanese market will grow at a CAGR of 12.7%.

Major drivers of growth in the bladder cancer market in the 7MM during 2015-2025 are expected to be the following –

• Immunotherapies, specifically PD-1 modulators, will see entry and/or increased incorporation into treatment algorithms.
• The launch of IO + IO combination therapies will fuel sales growth due to the premium pricing of these combination regimens.
• Increased incident cases of bladder cancer across the 7MM will increase the drug treatable patient population.
• Introduction of pipeline agents CG-0070, Vicinium, and Cyramza will expand treatment options for bladder cancer patients.

Historically, the bladder cancer market has been highly generic, with BCG and chemotherapies dominating the landscape. However, with the launch of Tecentriq and the subsequent launches of other PD-1 modulators, the bladder cancer treatment algorithms are expected to change during the forecast period. Though these PD-1 modulators are expected to have a significant impact on the treatment of bladder cancer, the reality is that a majority of patients (estimated to be upwards of 70%) will not respond to these drugs. Thus, pharmaceutical companies are looking at various ways to expand the treatable patient population.

While big pharma companies are focused on “me-too” PD-1 modulators, smaller companies are developing drugs with novel mechanisms of action (MOAs). Cold Genesys, Eleven Biotherapeutics, and FKD Therapies Oy all have late-stage candidates in the NMIBC setting that have distinctive MOAs. GlobalData believes that the bladder cancer market is an attractive prospect for these companies due to the combination of a high level of unmet need and relatively low regulatory hurdles, which provides a suitable risk-reward balance for developers with limited financial resources.

The report “OpportunityAnalyzer: Bladder Cancer – Opportunity Analysis and Forecasts to 2025” provides overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In particular, this report provides the following –

• Topline Bladder cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
• Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting bladder cancer therapeutics sales in the 7MM.
• Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
• Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Altor Bioscience, AstraZeneca, BioCancell, Bristol-Myers Squibb, Chugai, Cold Genesys, Eleven Biotherapeutics, Eli Lilly & Co., Endo Pharmaceuticals, Exelixis, FKD Therapies Oy, Immunomedics, MedImmune, Merck & Co., Merck KgAa, OncoGenex, Ono Pharmaceutical, Pfizer, Pierre Fabre Medicament, Roche.

Scope

• Overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
• Topline Bladder cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
• Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting bladder cancer therapeutics sales in the 7MM.
• Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
• Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the bladder cancer therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.